Trials / Completed
CompletedNCT02351024
Phase I Study PK Study With OXP005 and Naprosyn
Study to Assess the Comparative Bioavailability and Pharmacokinetics of Naproxen From OXP005 Tablets (Test) And Naprosyn® Tablets (Reference) in Normal, Healthy, Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Oxford Pharmascience Ltd · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The Sponsor is developing a new form of naproxen (the study drug, OXP005), for the potential treatment of rheumatic and painful conditions. The study will compare the study drug to an already marketed formulation of prescription strength naproxen (Naprosyn® the reference product) by looking at how a single dose of the drug is taken up by the body. The safety and tolerability of the drug will also be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OXP005 | |
| DRUG | Naprosyn® |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2015-01-30
- Last updated
- 2015-04-01
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02351024. Inclusion in this directory is not an endorsement.